You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 57 No. 11, November 2000 TABLE OF CONTENTS
  Archives
  •  Online Features
  Neurological Review
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (37)
 •Contact me when this article is cited
 Related Content
 •Related article
 •Similar articles in this journal
 Topic Collections
 •HIV/AIDS
 •Amyotrophic Lateral Sclerosis
 •Motor Neuron Disease
 •Movement Disorders
 •Neuromuscular diseases
 •Parkinson Disease/ Parkinsonian Disorders
 •Review
 •Genetic Disorders
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Apolipoprotein E and Neuromuscular Disease

A Critical Review of the Literature

Richard S. Bedlack, MD, PhD; Warren J. Strittmatter, MD; Joel C. Morgenlander, MD

Arch Neurol. 2000;57:1561-1565.

Molecular mechanisms that alter the incidence and rate of neuromuscular disease progression are, in many cases, only partially understood. Several recent studies have asked whether apolipoprotein E (apoE for the protein, APOE for the gene) influences these aspects of specific neuromuscular disorders, as it does in central nervous system disorders such as Alzheimer disease. Although these studies are open to methodological criticism, several interesting trends have emerged. First, the APOE4 allele seems to be associated with an increased risk for developing certain neuromuscular diseases, including diabetic neuropathy and human immunodeficiency viral neuropathy. Second, this allele appears to be associated with faster progression of some neuromuscular diseases, including diabetic neuropathy and possibly motor neuron disease. Third, the APOE2 allele seems to confer protection against developing certain neuromuscular diseases, including the amyotrophic lateral sclerosis (ALS)/parkinsonism/dementia complex of Guam. Finally, this allele is associated with a better prognosis in neuromuscular diseases such as motor neuron disease. The effect of various APOE alleles on neuromuscular diseases therefore parallels their influence on central nervous system diseases.


From the Division of Neurology, Duke University Medical Center, Durham, NC.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED ARTICLE

Archives of Neurology Reader's Choice: Continuing Medical Education
Arch Neurol. 2000;57(11):1661-1662.
FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

How citation distortions create unfounded authority: analysis of a citation network
Greenberg
BMJ 2009;339:b2680-b2680.
ABSTRACT | FULL TEXT  

Ceramide Is Responsible for the Failure of Compensatory Nerve Sprouting in Apolipoprotein E Knock-Out Mice
Maysinger et al.
J. Neurosci. 2008;28:7891-7899.
ABSTRACT | FULL TEXT  

Apolipoprotein E Gene Polymorphisms and Retinal Vascular Signs: The Atherosclerosis Risk in Communities (ARIC) Study
Liew et al.
Arch Ophthalmol 2007;125:813-818.
ABSTRACT | FULL TEXT  

Impaired reinnervation in HIV infection following experimental denervation
Hahn et al.
Neurology 2007;68:1251-1256.
ABSTRACT | FULL TEXT  

The Role of Apolipoprotein E Gene Polymorphisms in Primary Open-angle Glaucoma
Ressiniotis et al.
Arch Ophthalmol 2004;122:258-261.
ABSTRACT | FULL TEXT  

Apolipoprotein E genotypes and clinical outcome in Guillain-Barre syndrome
Pritchard et al.
J. Neurol. Neurosurg. Psychiatry 2003;74:971-973.
ABSTRACT | FULL TEXT  

APOE genotype is a risk factor for neuropathy severity in diabetic patients
Bedlack et al.
Neurology 2003;60:1022-1024.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2000 American Medical Association. All Rights Reserved.